AAPL 154.88 +1.84 (+1.20%)MSFT 105.38 +0.38 (+0.36%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)
AAPL 154.88 +1.84 (+1.20%)MSFT 105.38 +0.38 (+0.36%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)

Balance Sheet ADMS Quote Adamas Phar

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
CashAndCashEqui 33 24 91
ShortTermInvest 74 90 82
Cash 107 114 173
AccountReceivab 1 1 0
Inventories 0 0 2
DeferredIncomeT 0 0 0
OtherCurrentAss 4 1 1
TotalCurrentAss 113 117 179
PPE 3 4 6
AccumulatedDepr -1 -1 -3
NetPPE 2 3 3
EquityAndOtherI 13 22 3
Goodwill 0 0 0
IntangibleAsset 0 0 0
OtherLTAssets 0 0 1
TotalNonCurrent 16 25 7
TotalAssets 129 142 186
ShortTermDebt 0 0 0
AccountsPayable 3 4 4
TaxesPayable 0 0 0
AccruedLiabilit 8 6 12
DeferredRevenue 0 0 0
OtherCurrentLia 0 0 0
TotalCurrentLia 12 10 17
Debt 0 0 103
DeferredTaxesLi 0 0 0
DeferredRevenue 0 0 0
OtherLTLiabilit 1 1 1
TotalNonCurrent 1 1 103
TotalLiabilitie 13 10 120
CommonStock 0 0 0
AdditionalPaidI 178 255 278
RetainedEarning -62 -122 -212
AccumulatedOthe 0 0 0
TotalStockholde 116 132 66
TotalLiabilitie 129 142 186
Adamas Pharmaceuticals Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Adamas Pharmaceuticals Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.